{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408517291
| IUPAC_name = (2''E'')-3-[4-(1''H''-imidazol-1-ylmethyl)phenyl]acrylic acid
| image = Ozagrel.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|ozagrel}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 82571-53-7
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 5282440
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = L256JB984D
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08327
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 11662
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 4445594

<!--Chemical data-->
| chemical_formula =  
| C=13 | H=12 | N=2 | O=2 
| molecular_weight = 228.24 g/mol
| smiles            = C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = SHZKQBHERIJWAO-AATRIKPKSA-N

}}

'''Ozagrel''' ([[International Nonproprietary Name|INN]]) is an [[antiplatelet agent]] working as a [[thromboxane A2]] synthesis inhibitor.<ref name="pmid3820396">{{cite journal |vauthors=Loo MH, Egan D, Vaughan ED, Marion D, Felsen D, Weisman S |title=The effect of the thromboxane A2 synthesis inhibitor OKY-046 on renal function in rabbits following release of unilateral ureteral obstruction |journal=J. Urol. |volume=137 |issue=3 |pages=571â€“6 |date=March 1987 |pmid=3820396 |doi= |url=}}</ref>

==References==
{{Reflist}}

{{Prostanoidergics}}

[[Category:Imidazoles]]


{{blood-drug-stub}}